Physics and AI Driven Precision Engineering of Novel Drugs

Health + Time : Priceless

We're Engineering New Treatments Atom by Atom

To help you live as healthy as possible for as long as possible

First-in-Class Drug Candidates to Change the Standard of Care for Every Disease We Address
More about our pipeline
Recent coverage
Our stories
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
Why there's more to life than making it to a ripe old age
The National describes how Verseon's drug programs place the company at the vanguard of preventing the chronic diseases and disabilities of ageing
NOVEMBER 4, 2022
Verseon Acquires Edammo to Deepen Drug Discovery Approach
Verseon deepens its AI capabilities by acquiring company focused on analyzing the "Small and Wide Data" typical in drug discovery
October 18, 2022
Exploring the Uncharted Chemical Universe for New Medicines
David Kita, Verseon’s CSO, shares his views on the future of computational drug discovery
September 28, 2022
No, AI by Itself Probably Won't Revolutionize Drug Development
Alphabet's DeepMind admits they can't predict drug-protein interactions; "It's just hype," says Adityo Prakash, Verseon's CEO
September 24, 2022
Verseon's PKIs to Battle Diabetic Vision Loss
Verseon's scientists consistently find unique drug candidates that have never been designed or synthesised by anyone else
September 22, 2022
Verseon's HAE Drug Candidates in Focus
Verseon's oral drug candidates will offer an alternative to injections for a rare but potentially fatal condition
September 16, 2022
Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments
"These novel compounds ... could help hundreds of millions of people around the world," says David Kita, Verseon's CSO
September 7, 2022
Challenges Facing AI in Drug Discovery
Adityo Prakash, Verseon’s CEO, discusses the way forward
September 1, 2022
Preventing Strokes and Heart Attacks Doesn’t Have to Come with the Risk of Life-threatening Bleeding
Verseon’s scientific journey to highly promising therapeutic candidates for cardiovascular disease appears in European Journal of Medicinal Chemistry
DECEMBER 14, 2022
Is AI just hype or a real revolution in pharma? It’s complicated
Verseon's CEO Adityo Prakash discusses the challenges and opportunities facing AI in drug discovery
NOVEMBER 17, 2022
Why there's more to life than making it to a ripe old age
The National describes how Verseon's drug programs place the company at the vanguard of preventing the chronic diseases and disabilities of ageing
NOVEMBER 4, 2022
Verseon Acquires Edammo to Deepen Drug Discovery Approach
Verseon deepens its AI capabilities by acquiring company focused on analyzing the "Small and Wide Data" typical in drug discovery
October 18, 2022
Exploring the Uncharted Chemical Universe for New Medicines
David Kita, Verseon’s CSO, shares his views on the future of computational drug discovery
September 28, 2022
No, AI by Itself Probably Won't Revolutionize Drug Development
Alphabet's DeepMind admits they can't predict drug-protein interactions; "It's just hype," says Adityo Prakash, Verseon's CEO
September 24, 2022
Verseon's PKIs to Battle Diabetic Vision Loss
Verseon's scientists consistently find unique drug candidates that have never been designed or synthesised by anyone else
September 22, 2022
Verseon's HAE Drug Candidates in Focus
Verseon's oral drug candidates will offer an alternative to injections for a rare but potentially fatal condition
September 16, 2022
Verseon Gains European Patent Protection for Potential Sight and Life-Saving Treatments
"These novel compounds ... could help hundreds of millions of people around the world," says David Kita, Verseon's CSO
September 7, 2022
Challenges Facing AI in Drug Discovery
Adityo Prakash, Verseon’s CEO, discusses the way forward
September 1, 2022
More News
Changing everything the world can expect from 21st Century Medicine
Continue to Company